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Involvement of the TGF- and
-catenin pathways in
pelvic lymph node metastasis in









Presence of pelvic lymph node metastases is the main prognostic factor in early stage
cervical cancer patients, primarily treated with surgery. e aim of this study was to
identify cellular tumor pathways associated with pelvic lymph node metastasis in early
stage cervical cancer. Gene expression proëles (Aﬀymetrix U133 plus 2.0) of 20 pa-
tients with negative (N₀) and 19 with positive lymph nodes (N+), were compared with
gene sets that represent well-known and novel pathway signatures (n=285). Diﬀeren-
tially expressed genes were identiëed using a random-variance t-test. Pathway analysis
showed signiëcant enrichment of the TGF- pathway in N₀ patients, while dysregu-
lation of the -catenin pathway was associated with N+. Of the most signiëcant 149
genes that were diﬀerentially expressed between N₀ and N+ tumors (P<0.001), ëve
genes were involved in -catenin signaling (TCF4, CTNNAL1, CTNND1/p120, DKK3
and WNT5a). Validation by immunostaining of tumors of 274 consecutive early stage
cervical cancer patients was performed for representatives of the identiëed pathways.
is analysis conërmed that positive immunostaining of Smad4 (TGF- pathway) was
related to N₀ (OR=0.20; 95%CI=0.06 – 0.66) and p120 positivity (-catenin pathway)
to N+ (OR=1.79; 95%CI=1.05 – 3.05). In conclusion, our study provides new insights
in the molecular mechanism of lymph node metastasis in cervical cancer. Pathway anal-
ysis of the microarray expression proële revealed that the TGF- and p120-associated










Standard treatment of early stage cervical cancer patients consists of radical hysterec-
tomy and pelvic lymphadenectomy. For this group of patients, the presence of lymph
node metastases is the most important prognostic factor (1). Early stage cervical can-
cer patients with negative lymph nodes have a 5-year survival of 90% vs. only 65% in
patients with lymph nodemetastases (2). Patients with lymph nodemetastases are there-
fore treated with adjuvant (chemo)radiation. However, the combination of surgery and
(chemo)radiation is associated with severe morbidity (3). If the presence of metastatic
lymph nodes could be predicted prior to treatment, primary chemoradiation could be
considered, which is equally eﬀective, but associated with a diﬀerent treatment-related
morbidity pattern.
Several histopathological characteristics such as tumor size, lymph vascular space in-
volvement and depth of invasion have been associated with lymph node metastases in
cervical cancer but none of these is of suﬃcient clinical relevance (4). Furthermore, var-
ious molecular tumor markers like the expression of vascular endothelial growth factor
(VEGF), and p16 have been reported to be related with lymph node metastases in cervi-
cal cancer (5,6), but presently nomarkers are available to predict lymph node status with
high sensitivity and speciëcity. Non- and minimal invasive diagnostic techniques, such
as sentinel lymph node biopsy are currently being explored to better identify patients
with disease outside the cervix (7).
Little is known about biological pathways involved in lymph node metastasis in cer-
vical cancer. Metastasis is a complex, multistep process involving decreased cell-cell
interaction, increased cell migration, disruption of the basal membrane, intravasation
into the circulation, survival of direct exposure to the immune system and extreme me-
chanic forces in the bloodstream, and ënally extravasation and growth in metastatic
sites (8). Apart from tumor-speciëc changes, many processes in the tumor microenvi-
ronment of the primary tumor have shown also to be important for initiation of the
metastatic potential at the primary site (9).
Gene expression proëling has provided tools to identify patterns of biological diﬀer-
ences between diﬀerent tumor types, cancers with diverse clinical outcome or treatment
responses (10,11). To get insight into the mechanism of lymph node metastasis in head
and neck (12), colorectal (13), and cervical cancer (14-17), gene expression proëling
has been used. However, in most studies little overlap was found between diﬀeren-
tially expressed genes, which may be due to a variety of methodological issues (18).
Explanations that have been debated extensively in the literature are the use of diﬀerent







from a large pool of probes (20). erefore, comparing gene expression proëles with
gene sets that represent unique pathways may provide more insight into the mechanism
of lymph node metastasis. Diﬀerent pathway analysis methods have been developed,
including Gene Set Enrichment Analysis (GSEA). GSEA is used to determine whether
pre-deëned gene sets available for example in the Kyoto Encyclopedia of Genes and
Genomes (KEGG) (21) and Biocarta data bases (http://www.biocarta.com/), show sig-
niëcant, concordant diﬀerences between two phenotypes (22). Another method has
recently been developed by Bild et al. (23). Experimentally generated expression signa-
tures using human primary mammary epithelial cell cultures (HMECs) that reìect the
activation of various oncogenic signaling pathways (c-Myc, H-Ras, c-Src, E2F3, and
-catenin) can be used to assess the activation probability of the oncogenic pathways
in individual expression proëles. Both methods have not been applied previously for
diﬀerentiating between lymph node negative and positive cervical cancer patients.
e aim of this study was to identify cellular tumor pathways associated with pelvic
lymph node status in patients with early stage cervical cancer. Apart from obtaining
more insights on the molecular processes of lymph node metastasis in early stage cervi-
cal cancer, our ëndings might contribute to individual treatment strategies. To identify
such pathways, expression array analysis was performed on a well deëned series of cer-
vical squamous cell carcinomas of patients with histologically conërmed lymph node
metastases (N+) vs. patients with histological and clinically conërmed negative lymph
nodes (N₀). Potential markers representing the predictive value of pathways were vali-
dated in a large consecutive series of early stage cervical cancer patients by immunohis-
tochemistry on tissue microarrays (TMA).
Materials and methods
Patients and tumor samples
Since 1980 clinicopathological characteristics of all cervical cancer patients referred to
the Department of Gynecological Oncology of the University Medical Center Gronin-
gen are prospectively collected in a database. For the present study, patients with stage
IB-IIA disease, primarily treated with surgery between 1980 and 2004 were selected
(n=337). Follow-up data were collected for at least ëve years. Staging was performed
according to FIGO guidelines. Primary treatment consisted of type 3 radical hysterec-
tomy and pelvic lymph node dissection. In case of poor prognostic factors, such as
lymph node metastases or positive resection margins, patients were treated with adju-








ëxed primary tumor tissue was collected. All tumor tissues were histological revised
and only tumor specimens with suﬃcient tumor cells were included in the study for
construction of the TMA. In 274 cases suﬃcient pre-treatment paraﬃn-embedded tis-
sue was available for TMA construction. 112/274 (41%) patients received adjuvant
(chemo)radiation. Median follow-up time for patients on the TMAwas 5.5 years (range
0.3 – 18.6). Since 1990, when suﬃcient material was available also pre-treatment fresh
frozen tumor tissue was stored. For the microarray experiment, we selected fresh frozen
primary cervical cancer tissue, containing at least 80% tumor cells, of patients with
histologically conërmed N₀ (n=20) and of patients with N+ (n=19). e N₀ and N+
groups were matched for age, FIGO stage and histology (all squamous cell carcinoma).
However, as expected the groups diﬀered regarding presence of lymphangioinvasion
(P=0.024) and inëltration depth (P=0.001). Patient and tumor characteristics are sum-
marized in Table 1. In the University Medical Center Groningen clinicopathologic and
follow-up data are prospectively obtained during standard treatment and follow-up and
stored in a computerized registration database. For the present study, all relevant data
were retrieved from this computerized database into a separate, anonymous database.
Patient identity was protected by study-speciëc, unique patient numbers. Codes were
only known to two dedicated data managers, who also have daily responsibility for the
larger database. In case of uncertainties with respect to clinicopathologic and follow-up
data, the larger databases could only be checked through the datamanagers, thereby as-
certaining the protection of patients’ identity. Using the registration database all tissue
specimens were identiëed by unique patient numbers and retrieved from the archives
of the Department of Pathology. erefore, according to Dutch law no further Institu-
tional Review Board approval was required (http://www.federa.org/).
Microarray experiments
From the frozen biopsies, four 10-m-thick sections were cut and used for standard
RNA isolation. After cutting, a 3-m-thick section was stained with hematoxylin/eosin
for histological examination and only tissues with >80% tumor cells were included.
RNA was isolated with TRIzol reagent (Invitrogen, Breda, the Netherlands) accord-
ing to manufacturer’s protocol. RNA was treated with DNAse and puriëed using the
RNeasy mini-kit (Qiagen, Westburg, Leusden, the Netherlands). e quality and quan-
tity of the RNAwas determined by Agilent Lab-on-Chip analysis. For labelling, 10 g of
total RNA was ampliëed by in vitro transcription using T7 RNA polymerase. Labelled
RNA samples were hybridized according to a randomized design to the human genome







Table 1 – Patient and tumor characteristics
Microarray N₀ * Microarray N+ † TMA‡
n=20 n=19 n=274
Age at diagnosis
Median 47.39 40.44 43.65
Range 31.53 – 72.71 29.10 – 72.51 23.67 – 84.65
n % n % n %
FIGO stage
Ib1 11 55% 10 53% 174 64%
Ib2 5 25% 6 32% 54 20%
IIa 4 20% 3 16% 46 17%
Histology
Squamous cell carcinoma 20 100% 19 100% 182 66%
Adenocarcinoma 0 0% 0 0% 74 27%
Other 0 0% 0 0% 18 7%
Grade of diﬀerentiation
Good/moderate 15 75% 10 53% 163 59%
Poor/undiﬀerentiated 4 20% 9 47% 106 39%
unknown 1 5% 0 0% 5 2%
Lymphangioinvasion
No 14 70% 6 32% 132 48%
Yes 6 30% 12 63% 142 52%
unknown 0 0% 1 5% 0 0%
Iníltration depth
0-10 mm 14 70% 3 16% 135 49%
10 mm 5 25% 14 74% 126 46%
unknown 1 5% 2 11% 13 5%
Tumor diameter
0-4 cm 14 70% 12 63% 198 72%
4 cm 6 30% 7 37% 76 28%
Lymph nodes
Negative 20 100% 0 0% 194 71%




with 200 l of hybridization cocktail solution and then placed in Genechip Hybridiza-
tion Oven 640 (Aﬀymetrix) rotating at 60 rpm at 45 °C for 16 h. After hybridization,
the arrays were washed on Genechip Fluidics Station 400 (Aﬀymetrix) and scanned us-
ing Genechip Scanner 3000 (Aﬀymetrix) according to the manufacturers’ procedure.








performed by ServiceXS (Leiden, the Netherlands, http://www.serviceXS.com) accord-
ing to Aﬀymetrix standards. Pre-processing of CEL ëles was performed with Aﬀymetrix
Expression Console software. Probe set expression summary was done using the Robust
Multi-array Average (RMA) algorithm. Quality of the microarray data was checked us-
ing histograms, box plots and a RNA degradation plot. Principal component analysis
(PCA) was performed for controlling the quality of the hybridizations (24).
Gene Set Enrichment Analysis (GSEA)
GSEA was performed with the software package GSEA 2.0, developed by the Broad
Institute of MIT and Harvard (22). Each gene was ranked according to its relative
diﬀerence in expression between the N₀ and N+ group using the Student’s t-statistic.
Ranked expression data for all annotated 20,606 genes (in case of more than one probe
per gene, the probe with the highest intensity was considered) were compared against
a large collection of biological gene sets to determine whether genes both at the top or
bottom of the ranked list were enriched in these functional gene sets. GSEA analysis
was performed separately with a total of 155 gene sets in the KEGG (21) and 125 gene
sets in the Biocarta data base. e gene sets used are available at the Molecular Sig-
nature Database (http://www.broadinstitute.org/gsea/msigdb/). Statistical enrichment
was determined using an empirical phenotype-based permutation test based on 1,000
permutations. Furthermore, for each functional set the false discovery rate (FDR) and
nominal P value were calculated. P values of <0.05 were considered statistically signif-
icant.
Oncogenic pathway activation
Bild et al. experimentally generated expression signatures using human primary mam-
mary epithelial cell cultures (HMECs) that reìect the activation of various oncogenic
signaling pathways (c-Myc, H-Ras, c-Src, E2F3, and -catenin) (23). Recombinant
adenoviruses were used to express the oncogenic activity in an otherwise quiescent cell.
Genes diﬀerently expressed between the quiescent cells and the transfected cells were
selected and were used in a model to predict the activation status of each of these ëve
oncogenic pathways. Publicly available software implementing these models (BinReg)
(23) was used to assess the activation probability of the oncogenic pathways in our 39
cervical tumor samples. In this analysis, it was expected to ënd a large diﬀerence in
expression patterns between the HMECs Bild et al. used to generate the oncogenic ex-







status is based solely on the expression data of the HMECs and does not take into ac-
count the expression diﬀerences between the HMECs and the cervical tumor samples.
is could potentially lead to unreliable activation probabilities. erefore, the HMECs
and cervical tumor samples were pooled and by applying Principle Component Anal-
ysis (PCA) we aimed to identify a Principal Component (PC) that explained variance
correlating with the diﬀerence between HMECs and cervical tumor samples (25,26).
By subtracting the variance explained by this PC it is possible to ëlter out the expression
diﬀerences between HMECs and cervical tumor samples. erefore, the variance ex-
plained by this PC was subtracted from our data set and these corrected cervical tumor
data was used for subsequent analysis with BinReg.
Class comparison
Class comparison was performed using the software package BRB Array Tools 3.7.0, de-
veloped by the Biometric Research Branch of the US National Cancer Institute
(http://linus.nci.nih.gov/BRB-ArrayTools.html). Diﬀerentially expressed probe sets
were identiëed using a parametric two-sample t-test (with random variance model) with
a signiëcance threshold of P<0.001. In addition, for each probe set the FDR was de-
termined (27). Finally, a global test was performed to assess the probability of getting
the observed number of identiëed signiëcant probe sets by chance, that is, under the
assumption that there is no diﬀerence in expression between the N₀ and N+ group. Dif-
ferentially expressed genes were ranked according to lowest FDR and lowest parametric
P value.
Immunohistochemical validation
Immunohistochemistry of the relevant proteins was performed on tissue microarrays
(TMAs). TMAs were constructed as previously described (28). For immunohisto-
chemistry, 3 m sections were cut from the TMAs. ese sections were mounted
on amino-propyl-ethoxy-silan (APES, Sigma-Aldrich, Diesenhofen Germany)-coated
glass slides. Slides were deparaﬃnized in xylene and rehydrated in ethanol. Anti-
gen retrieval was performed by boiling the slides in a microwave oven in citrate (pH
6.0) for 15 min. Endogenous peroxidase was blocked by incubation with 0.3% hy-
drogen peroxidase for 30 min. Slides were incubated with a mouse monoclonal anti-
bodies against -catenin (clone 14; dilution 1:1000; BD Transduction Laboratories,
Franklin Lake, NJ) and p120 (clone 98; dilution 1:100; BD Transduction Labora-








1:400; Santa Cruz Biotechnology, Santa Cruz, CA) and pSmad2 (clone 138D4; di-
lution 1:25; Cell Signaling, Danvers, MA) overnight at 4ǽC. For immunodetection
of -catenin and Smad4, RAMHRP (dilution 1:100; Dako, Copenhagen, Denmark)
and GARHRP(dilution 1:100; Dako) were used. For immunodetection of pSmad2
GARHRP (dilution 1:100; Dako) and RAGHRP(dilution 1:100; Dako) and for p120
the EnVision horseradish peroxidase system (Dako) were used. Staining was visualized
by 3’3-diaminobenzidinetetrahydrochloride and counterstaining was performed with
hematoxylin. Normal cervical epithelium was used as a positive control. Scoring was
performed by two independent observers without knowledge of clinical data. A con-
cordance of more than 90% was found for all stainings. e discordant cases were
reviewed and scores were reassigned on consensus of opinion. Staining intensity was
semiquantitatively scored as negative (0), weak positive (1), moderate positive (2), and
strong positive (3). Also the percentage of positive cells was recorded. Positive Smad4
expression was deëned as presence of both >50% moderate/strong positive nuclear and
moderate/strong positive cytoplasmic staining (29). -catenin and p120 positivity was
deëned as membranous staining at any intensity (1-3) in >50% of cells (30). Statistical
analysis was performed with SPSS 16.0 for Windows (SPSS Inc., Chicago, IL). Asso-
ciations between immunostainings and lymph node metastases were compared using
logistic regression models, in which immunostainings were used as dependent factors
and the clinicopathological characteristics as independent factors. P values of <0.05
were considered statistically signiëcant.
Table 2 – Results of Gene Set Enrichment Analysis
using pathway deënitions of Biocarta and KEGG
Pathway P value FDR‡ Enriched in
NFAT (Biocarta) 0.004 0.252 N₀*
ALK (Biocarta) 0.013 0.269 N₀*
BAD (Biocarta) 0.016 0.492 N₀*
TGF- (KEGG) 0.027 1.000 N₀*
Glycosphingolipid Biosynthesis Neo Lactoseries (KEGG) 0.039 1.000 N+†










Table 3 – Predicted probabilities for all 5 oncogenic pathways
Lymph node negative
CXCA* -catenin H-Ras c-Src c-Myc E2F3
12 0.387 0.868 0.635 0.690 0.287
07 0.792 0.278 0.655 0.702 0.562
11 0.249 0.593 0.487 0.596 0.738
20 0.647 0.180 0.539 0.485 0.572
08 0.331 0.331 0.352 0.704 0.952
10 0.368 0.715 0.500 0.536 0.434
13 0.793 0.129 0.718 0.304 0.366
19 0.539 0.442 0.625 0.590 0.334
14 0.625 0.278 0.733 0.499 0.121
18 0.552 0.557 0.555 0.428 0.296
16 0.287 0.512 0.275 0.826 0.982
15 0.465 0.513 0.528 0.566 0.238
17 0.406 0.485 0.526 0.582 0.164
09 0.256 0.601 0.448 0.370 0.351
02 0.427 0.410 0.478 0.474 0.783
05 0.594 0.200 0.458 0.475 0.850
03 0.498 0.557 0.592 0.344 0.158
06 0.384 0.482 0.425 0.392 0.488
04 0.542 0.584 0.516 0.583 0.812
01 0.535 0.338 0.497 0.443 0.503
Lymph node positive
CXCA* -catenin H-Ras c-Src c-Myc E2F3
23 0.673 0.299 0.601 0.583 0.808
22 0.750 0.208 0.704 0.452 0.288
36 0.535 0.439 0.539 0.438 0.328
39 0.686 0.251 0.614 0.417 0.240
21 0.608 0.550 0.530 0.360 0.682
38 0.518 0.475 0.454 0.700 0.405
35 0.487 0.372 0.523 0.636 0.540
37 0.572 0.615 0.574 0.514 0.447
24 0.584 0.573 0.626 0.574 0.371
34 0.901 0.180 0.858 0.339 0.167
27 0.570 0.762 0.615 0.597 0.312
29 0.579 0.386 0.601 0.519 0.558
30 0.539 0.488 0.562 0.372 0.235
31 0.708 0.199 0.492 0.486 0.598
28 0.724 0.283 0.671 0.418 0.440
26 0.620 0.527 0.601 0.483 0.400
25 0.654 0.257 0.626 0.441 0.459
32 0.724 0.122 0.699 0.344 0.216
33 0.705 0.246 0.596 0.609 0.278
*Cervical cancer ID
Results
Biological pathways associated with pelvic lymph node status
GSEA using biological pathway deënitions according to KEGG and Biocarta data bases
revealed that ëve pathways (TGF-, NFAT, ALK, BAD and PAR1 pathway) were signif-
icantly enriched in theN₀ group, whereas only one pathway (Glycosphingolipid Biosyn-
thesis Neo Lactoseries pathway) was enriched in the N+ group (Table 2).
Analyzing the association between oncogenic pathways and lymph node status using
expression signatures that reìect the activation of ëve major oncogenic signaling path-
ways (c-Myc, H-Ras, c-Src, E2F3, and -catenin) revealed that the activation prob-
abilities of the oncogenic -catenin pathway correlated highly signiëcantly with N+
(P=0.001). Table 3 shows the predicted probabilities for all ëve oncogenic pathways. A
scatter plot of the activation probability of -catenin for our 39 cervical tumor samples
shows that tumor samples with a low or high probability of -catenin activation are








Figure 1 – Scatter plot of the activation probability of -catenin
























Individual genes of the -catenin pathway are related to lymph node
status
We identiëed probe sets that were diﬀerentially expressed between N₀ and N+ samples
using a random-variance t-test. Using this analysis, we identiëed 188 probe sets that
are diﬀerentially expressed at a signiëcance level of P<0.001 (Table 5). e probability
of ënding at least 188 signiëcant probe sets by chance, that is, under the assumption
that there are no diﬀerences between the N₀ and N+ groups was P=0.035. ese 188
probe sets represented 149 unique genes of which 46 genes were upregulated and 103
genes were downregulated in the N+ group. Interestingly, 14 probe sets representing
ëve unique genes (TCF4, CTNNAL1, DKK3, CTNND1/p120 and WNT5a) belong to
the -catenin pathway. is is in good agreement with our pathway analysis using all
genes.
Immunohistochemical validation of the TGF- and -catenin path-
way
To validate the association between the lymph node status in early stage cervical cancer
and the oncogenic TGF- signaling and -catenin pathways, we performed immuno-
histochemistry using antibodies directed against proteins that are representative for both







cancer tissues of 274 patients.
Phosphorylation of Smad2/3 and concomitant translocation into the nucleus is an
important step in transforming growth factor  (TGF-) signaling and expression of
Smad4 is an essential partner of Smad2/3 in the formation of transcriptional complexes
(31,32). To validate whether pSmad2 and/or Smad4 staining on the TMA are repre-
sentative for the whole tumor, ërst whole tumor slides of a small series of 20 randomly
selected cervical cancer tissues were immunostained. is immunostaining revealed
that only Smad4 staining was homogeneous (data not shown). erefore, Smad4 stain-
ing on the TMA reìects best the staining of the whole tumor. irty ëve out of 255
evaluable cervical carcinomas showed positive Smad4 staining (see Fig. 2 for represen-
tative immunostainings). Univariate logistic regression analysis of various clinicopatho-
logical features revealed that Smad4 positivity was not only related to N₀, (OR=0.20;
95%CI=0.06 – 0.66) but also to inëltration depth <10 mm (OR=0.35; 95%CI=0.16
– 0.76) (Table 4).
To validate whether -catenin signaling is associated with the presence of lymph
node metastases in cervical cancer, immunohistochemical staining was performed for -
catenin, a key protein in the canonical -catenin pathway (33). In addition, we included
the immunostaining for CTNND1/p120 that is involved in non-canonical -catenin
signaling (34) and was one of the ëve -catenin related transcripts present in the list of
149 diﬀerentially expressed genes (188 probe sets) (Table 5). Positive p120 immuno-
staining was observed in 112/268 (42%) and positive -catenin in 140/272 (51%) pa-
tients (see Fig. 2 for examples). Logistic regression analysis revealed no association
between -catenin protein expression and presence of lymph node metastases (Table
4). However, positive p120 staining was associated with N+ (OR=1.79; 95%CI=1.05
– 3.05), in agreement with our microarray results.
Discussion
In the present study, pathways associated with pelvic lymph node metastases in 39 (20
N₀ and 19 N+) early stage cervical cancer patients were identiëed. Our analysis of well-
known and novel (n=285) pathway signatures revealed an association of lymph node
metastases with only few gene sets or signatures, including two well-known oncogenic
biological gene sets. Enrichment of the TGF- pathway was related to N₀, while onco-
genic pathway activation of -catenin was associated with N+ patients. e association
of both the TGF- and the -catenin signaling pathway with lymph node metastases








Table 4 – Logistic regression analysis for the relation between
clinicopathological characteristics and stainings
Smad4 (n=255) Smad4 - Smad4 + Smad4 +
n/total % n/total % OR † (95%CI) ‡
Age (continuous) 1.00 (0.98 – 1.03)
Age 43 111/220 50% 21/35 60%
Stage Ib2 83/220 38% 11/35 31% 0.76 (0.35 – 1.62)
SCC* 150/206 73% 20/31 65% 0.68 (0.31 – 1.51)
Poor diﬀerentiation 87/216 40% 17/34 50% 1.48 (0.72 – 3.06)
Lymphangioinvasion 119/220 54% 15/35 43% 0.64 (0.31 – 1.31)
Inëltration depth 10 mm 111/207 54% 10/35 29% 0.35 (0.16 – 0.76)§
Tumor diameter 4 cm 65/220 30% 6/35 17% 0.49 (0.20 – 1.24)
Positive lymph nodes 71/220 32% 3/35 9% 0.20 (0.06 – 0.66)§
p120 (n=268) p120 - p120 + p120 +
n/total % n/total % OR † (95%CI) ‡
Age (continuous) 1.00 (0.98 – 1.02)
Age 43 78/156 50% 60/112 54%
Stage Ib2 58/156 37% 40/112 36% 0.94 (0.57 – 1.56)
SCC* 88/142 62% 90/108 83% 3.07 (1.67 – 5.64)§
Poor diﬀerentiation 64/153 42% 41/110 37% 0.83 (0.50 – 1.37)
Lymphangioinvasion 70/156 45% 68/112 61% 1.90 (1.16 – 3.11)§
Inëltration depth 10 mm 70/147 48% 54/108 50% 1.10 (0.67 – 1.81)
Tumor diameter 4 cm 44/156 28% 31/112 28% 0.97 (0.57 – 1.67)
Positive lymph nodes 37/156 24% 40/112 36% 1.79 (1.05 – 3.05)§
-catenin (n=272) -catenin - -catenin + -catenin +
n/total % n/total % OR † (95%CI) ‡
Age (continuous) 1.01 (0.99 – 1.03)
Age 43 63/132 48% 76/140 54%
Stage Ib2 48/132 36% 52/140 37% 1.03 (0.63 – 1.69)
SCC* 81/126 64% 101/129 78% 2.00 (1.15 – 3.49)§
Poor diﬀerentiation 52/132 39% 53/135 39% 0.99 (0.61 – 1.62)
Lymphangioinvasion 63/132 48% 77/140 55% 1.34 (0.83 – 2.16)
Inëltration depth 10 mm 64/125 51% 61/134 46% 0.80 (0.49 – 1.30)
Tumor diameter 4 cm 38/132 29% 38/140 27% 0.92 (0.54 – 1.57)
Positive lymph nodes 37/132 28% 43/140 31% 1.14 (0.67 – 1.92)
e proportion of patients with less than 2





munohistochemistry. Immunostaining of Smad4 and p120 representing the TGF-
and -catenin signaling pathway, respectively, conërmed the association with lymph
node metastasis in early stage cervical cancer.
Until now, all studies using microarray platforms for diﬀerentiating between patient







Figure 2 – Representative immunostaining patterns for Smad4, p120,












and individual genes present in these proëles (14-17). Another approach is to identify
biological pathways that are involved in biological diﬀerences between cancers, using
pathway analysis methods on all genes that are diﬀerentially expressed between two
phenotypes. For example, Lagarde et al. identiëed pathways that diﬀerentiated between
N₀ and N+ esophageal adenocarcinomas (35). Furthermore, Crijns et al. identiëed
pathways contributing to clinical outcome of serous ovarian cancer (24). Interestingly,
many of these pathways were known for being important in carcinogenesis or cancer
progression, which indicates the strength of this approach. To our knowledge, we are
the ërst to identify pathways for discriminating between N₀ and N+ cervical cancer
patients using pathway analysis methods.
Our analysis showed that TGF- is one of the most important pathways aﬀecting
the metastatic potential in early stage cervical cancer. First, of all 280 tested unique








cantly enriched in N₀ (Table 2). Binding of the TGF- ligand to its receptors initiates
intracellular signaling by phosphorylation of Smad2 and Smad3. ese phosphorylated
Smads then bind to Smad4 and translocate into the nucleus, where this Smad complex
is involved in regulation of gene transcription (31,32). Immunostaining using Smad4
of 255 early stage cervical carcinomas conërmed that TGF- pathway activation was re-
lated to absence of lymph node metastases. Early in carcinogenesis, the TGF- pathway
contributes to tumor suppression, for example by stimulating apoptosis and inhibition
of growth (31,32) However, later in the process of tumor progression or in invasive
cancer, oncogenic activity of TGF- signaling is predominantly present, including in-
creased migration and invasiveness, which may result in metastases. is transition
from a tumor suppressor to an oncogenic pathway can be due to various alterations in
TGF- signaling, such as loss of Smad signaling and activation of Smad-independent,
more oncogenic pathways, such as MAPK pathways (31,32). Furthermore, TGF- is
directly involved in the formation of metastases, as it contributes to the establishment
and outgrowth of lung and bone metastases in breast cancer models (36,37). Smad4
downregulation is associated with TGF- downregulation and has been implicated in
cervical cancer (29) and metastatic mouse models (36). e downregulation of Smad4
in N+ is consistent with these data and establishes TGF- as one of the pathways af-
fecting the metastatic potential in early stage cervical cancer.
In addition to the TGF- pathway, GSEA revealed that the NFAT, ALK, BAD, and
PAR1 pathways were signiëcantly enriched in the N₀ group and the Glycosphingolipid
Biosynthesis Neo Lactoseries pathway in the N+ group (Table 2). Presently, little is
known about these pathways and whether they are associated with the metastatic be-
havior of tumor cells. e elucidation of the possible involvement of these pathways in
lymph node metastasis is subject of future interest in our laboratory.
A limitation of GSEA is that pathway activation can not be assessed for an individual
patient. erefore, another strategy was developed in which expression signatures are
experimentally generated to reìect activation status of various oncogenic signaling path-
ways (23). Our study indicates that N+ patients had a higher probability of -catenin
pathway activation than N₀ patients, pointing to a role for the -catenin pathway in
formation of lymph node metastases. Interestingly, the gene set of 188 diﬀerentially
expressed probe sets between N₀ and N+, included ëve unique genes involved in the
-catenin-pathway including p120 (CTNND1 or catenin delta 1), CTNNAL1 (catenin
alpha-like 1), DKK3 (dickkopf homolog 3), WNT5a, and TCF4 (transcription factor 4),
but did not include -catenin. In good agreement with these ëndings, immunohisto-







with N+. -catenin is an important member of both the WNT-signaling pathway and
the cell-cell adhesion pathway. However, immunohistochemical analysis revealed no
relation between -catenin and lymph node metastases, which is in agreement with
other studies (30,38) and indicates that the canonical Wnt/-catenin pathway (con-
taining -catenin, Wnt1, APC) is not involved in mediating the invasive potential in
cervical cancer. In normal cervical epithelium, -catenin is involved in E-cadherin me-
diated cell-cell adhesion, by binding to the cytoplasmic domain of E-cadherin. Loss of
E-cadherin causes disruption of cell adhesion and therefore might contribute to metas-
tases (33,34). P120 (also referred to as CTNND1 or delta-catenin) is a member of
the catenin family and was originally reported to stabilize the cadherin-complex by di-
rect interaction with the proximal domain of E-cadherin (33,34). On the other hand,
p120 (especially p120 isoform 1) promotes cell motility and invasiveness in cancer (39).
P120 was reported to exert its eﬀects by modulating the activities of Rho GTPases, for
example by inhibiting activity of RhoA and activation of Rac and Cdc42 (39,40). To
our knowledge our study is the ërst that reports that p120 expression is associated with
presence of lymph node metastases in early stage cervical cancer. e link of p120 to
Rho GTPases in activating the metastatic potential might also oﬀer new opportunities
for therapy since invasion has been inhibited successfully using Rho-inhibitors (41).
us, both the TGF- and the -catenin pathway are related to lymph node metas-
tases in cervical cancer. is indicates an important role for epithelial to mesenchymal
transition (EMT), as both pathways may contribute to EMT. EMT is characterized by
loss of the epithelial phenotype of cells and cells adopt a mesenchymal phenotype. It can
be induced by alterations in TGF- signaling, such as loss of Smad4 (42) and EMT is
characterized by loss of E-cadherin, with disruption of cell adhesion as a consequence.
Furthermore, EMT results in increased motility of cells, and increased invasion. All
these processes contribute to the formation of metastases (43,44). TGF- signaling
and -catenin also cooperate in EMT. Loss of E-cadherin causes increased -catenin
signaling, which cooperates with autocrine TGF- signaling to maintain an mesenchy-
mal phenotype (45). us, deregulation of both the TGF- and the -catenin pathway,
as observed in our study, indicates a role for EMT in lymph node metastasis in cervi-
cal cancer. Interestingly, miR-200a which is known for inhibition of TGF--mediated
EMT by maintaining the epithelial phenotype through regulating expression of the E-
cadherin transcriptional repressors ZEB1 and ZEB2 (46), was found to be a suppressor
of metastasis in cervical cancer (47). is supports the importance of EMT in lymph
node metastasis in cervical cancer.








choice of treatment for early stage cervical cancer patients. No markers are currently
available for accurate prediction of lymph node metastases before primary surgery. Ex-
pression levels of proteins such as Smad4 and p120 as representatives for the TGF-
signaling and -catenin pathway respectively, can also not accurately predict lymph
node metastases. However, more detailed analysis of these pathways might result in the
identiëcation of additional markers that will increase the clinical sensitivity en speci-
ëcity. More importantly, by identifying pathways involved in lymph node metastasis
in early stage cervical cancer, new opportunities for pathway targeted therapy can be
considered to inhibit the metastatic potential, as reported for both pathways (48,49).
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